⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Bisphosphonates and Aging
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-16 — RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: cross-connection with rankl-inhibitors: Both are bone-pathway drugs now being probed for extraskeletal aging endpoints; RANKL inhibition is entering an explicit muscle-aging (sarcopenia) trial, extending the bone→muscle repurposing question. (novelty: 3)
- 2026-09-18 — RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis: cross-connection with denosumab-rankl: Both are approved bone-remodeling therapies now being probed for extra-skeletal aging effects — denosumab into muscle/sarcopenia, bisphosphonates into broader aging phenotypes. (novelty: 3)
Open questions
Related
Contributing findings
The Challenge of Cheap Interventions and Expensive Clinical Trials
07-sep-2026
novelty 2
per-area 2
mentions